SeaStar Medical Holding Corporation ICU

DENVER, Oct. 02, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that a late-breaking abstract evaluating the results of the post-approval SAVE Registry data has been accepted for a special late-breaker poster presentation at the upcoming American Society of Nephrology (ASN) Kidney Week 2026 meeting, t

New codes streamline hospital billing, enable tracking of clinical outcomes, and expand access to QUELIMMUNE ® (SCD-PED) therapy Universal codes establish a framework to enable billing for future potential SCD indications that require renal replacement therapy DENVER, Oct. 01, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss o

Dr. Chung to deliver an oral presentation highlighting QUELIMMUNE®, an advanced extracorporeal therapy for critically ill pediatric patients with acute kidney injury (AKI) DENVER, Sept. 29, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that its Chief Medical Officer, Kevin Chung, M.D., will deliver a

Prestigious honor recognizes Dr. Humes’ pioneering work in developing the Selective Cytopheretic Device (SCD) therapy, commercialized by SeaStar Medical as QUELIMMUNE® for critically ill pediatric patients with acute kidney injury (AKI) SeaStar Medical’s SCD development pipeline of indications holds promise for multiple additional indications DENVER, Sept. 24, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformati

DENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will participate in the upcoming HC Wainwright 28th Annual Global Investment Conference being held September 14 to 16, 2026 in New York City. The SeaStar Medical presentatio

By David Bautz, PhD NASDAQ: ICU READ THE FULL ICU RESEARCH REPORT Business Update YoY Revenue Growth of 82% for QUELIMMUNE SeaStar Medical Holding Corp. (NASDAQ: ICU) is increasingly validating its commercial strategy for QUELIMMUNE, as exhibited by an 82% YoY growth in revenue for the second quarter of 2026, while simultaneously establishing the reimbursement infrastructure and

Pediatric adoption doubles to 20 top children's hospitals, while Neutralize-AKI trial enrollment accelerates toward late-2027 PMA submission.

Added 3 top-rated children’s hospitals to QUELIMMUNE® pediatric acute kidney injury (AKI) customer base, increasing net revenue 82% versus second quarter 2025 Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial in adult patients with AKI Obtained ICD-10-PCS codes to enable standardized inpatient hospital billing for its selective cytopheretic device (SCD) therapy, including QUELIMMUNE Webcast today at 4:30 pm Eastern Time DENVER, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Hol

DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its second quarter financial results after market close on Wednesday, August 12, 2026, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, August 12, 202

Sponsors educational summit of leading pediatric AKI health care experts Announces best practices webinar to further advance new treatment options DENVER, July 14, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that it is a proud sponsor of key initiatives to advance the treatment of pediatric patient

NEW YORK CITY, NY / ACCESS Newswire / June 30, 2026 / Investor Summit Group is excited to share that the presentations from our Q2 Virtual Conference are now available on-demand. If you missed the live event, now's your chance to catch up at your ...

NEW YORK, NY / ACCESS Newswire / June 23, 2026 / The Investor Summit today announced the lineup of public companies scheduled to present at its upcoming Virtual June 24-25, 2026 event. Event Details: Virtual Presentations on Wednesday June 24, 2026Virtual ...

Enables standardized inpatient hospital billing for QUELIMMUNE® (SCD-PED) therapy Universal code paves the way for billing of future potential SCD therapies requiring renal replacement therapy DENVER, June 23, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that its Selective Cytopheretic Device (SCD)

DENVER, June 22, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at the Virtual Investor Summit Conference on Wednesday, June 24th at 10:30 am Eastern Time. Interested investors can register and view the live presentation her

By David Bautz, PhD NASDAQ: ICU READ THE FULL ICU RESEARCH REPORT Business Update On Track to Complete Enrollment in Phase 3 NEUTRALIZE-AKI Trial by End of 2026 SeaStar Medical Holding Corp. (NASDAQ: ICU) is currently conducting the NEUTRALIZE-AKI pivotal study to assess the safety and efficacy of the SCD in adults with AKI. It is a two-arm, randomized, open label, controlled, multi-center trial

Moby summary of SeaStar Medical Holding Corporation's Q2 2026 earnings call